ARYx Sees Successful Drug Cardiac Safety Results

ARYx Therapeutics reported positive results of Thorough QT, a cardiac safety study for its prokinetic agent ATI-7505 conducted in conjunction with Procter & Gamble.

The agent is in Phase II clinical trials for chronic constipation and functional dyspepsia.

Results showed that electrocardiographic effects at therapeutic and supra-therapeutic doses were negative, ARYx said.